Description: Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.
Home Page: www.biocuretech.com
1055 West Hastings Street
Vancouver,
BC
V6E 2E9
Canada
Phone:
604 609 7146
Officers
| Name | Title |
|---|---|
| Dr. Björn Cochlovius Ph.D. | President |
| Mr. Konstantin Lichtenwald B.B.A., CPA, CGA | CFO, Corporate Secretary & Director |
| Mr. Yee Sing Cheng | CEO & Director |
| Mr. Marco Nonni | Consultant |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |